{"id":"W4412203029","doi":"10.1158/1078-0432.ccr-25-0100","title":"Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; EMD Serono; MacroGenics; Regeneron Pharmaceuticals; Belfer Center for Science and International Affairs, Harvard University; Seagen; Gilead Sciences; AstraZeneca; Pfizer; Coherus Biosciences; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Tolerability; Combination therapy; Rash; Internal medicine; Adverse effect; Pharmacodynamics; Cetuximab; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Phases of clinical research; Oncology; Gastroenterology; Pharmacology; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001134513,0.001629606,0.002053694,0.0003491667,0.0004052515,0.0009290127,0.0008159022,0.001214092,0.002596422],"category_scores_gemma":[0.0006378134,0.0005117057,0.0009417963,0.0003750365,0.001155738,0.0008273031,0.0002707093,0.003727898,0.0008310897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009890284,"about_ca_system_score_gemma":0.00158674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008381391,"about_ca_topic_score_gemma":0.001533923,"domain_scores_codex":[0.9996486,0.0001517036,0.00001689012,0.00005775036,0.00004233714,0.00008279997],"domain_scores_gemma":[0.9993581,0.00009265231,0.0001418952,0.00005366857,0.00003868918,0.0003149774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7098134,0.105775,0.003628544,0.0007566837,0.001157669,0.0002658381,0.000277244,0.003976123,0.1014789,0.000305218,0.002713556,0.06985188],"study_design_scores_gemma":[0.4373705,0.5465097,0.004813694,0.00002282758,0.0002914497,0.0002189946,0.0000402934,0.00144764,0.00783826,0.000128371,0.001298771,0.00001954566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951219,0.001310358,0.0003997541,0.0002909019,0.0001095832,0.001336107,0.0003834215,0.0000669458,0.0009809148],"genre_scores_gemma":[0.9931006,0.001083812,0.001261465,0.000376691,0.0001351842,0.001420436,0.001049744,0.0000176506,0.00155433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002596422,"threshold_uncertainty_score":0.008685827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1652581670627115,"score_gpt":0.5464717634505963,"score_spread":0.3812135963878849,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}